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Introduction
In the last thirty years a large body of observational and 
epidemiological studies has described an association 
between obstructive sleep apnoea (OSA) and increased 
incidence of vascular morbidity and mortality (1-4). 
The findings of physiological studies and clinical trials 
have established that pathophysiological consequences of 
OSA such as sympathetic activity, intermittent hypoxia and 
oxidative stress as well as intrathoracic pressure swings play 
a key role in the development of vascular dysfunction in 
patients with OSA. Therefore a biological plausibility for a 
causal association between OSA and cardiovascular events 
can be assumed (5-7). 
Continuous positive airway pressure (CPAP) is the 
gold standard therapy for OSA and has been proven to 
reduce daytime sleepiness and enhance quality of life in 
patients with OSA (8). Moreover, several observational 
studies suggested an association between CPAP therapy 
and reduced cardio- and cerebrovascular morbidity and 
mortality in patients with OSA. The mechanisms involved 
in this beneficial effect of CPAP on the vascular system 
likely include a reduction of blood pressure (BP) and 
improvement of vascular function (9-12). 
The aim of this review was to summarize the currently 
established effects of CPAP on BP and vascular function in 
patients with OSA.
CPAP effects on BP
One major mechanism underpinning the association between 
OSA and cardiovascular disease is likely to be sustained 
arterial hypertension, and this association may possibly 
be enhanced by frequent nocturnal acute BP rises. The 
repetitive episodes of obstructive apnoeas and hypopnoeas 
are often associated with arousals and intermittent hypoxia, 
both of which lead to increased sympathetic nervous system 
activity and consequent considerable transient increases 
in arterial BP which can be as high as 80 mmHg. CPAP 
treatment has been shown to not only effectively abolish 
apnoeas, hypopnoeas and oxygen desaturations, but also to 
prevent arousals and, thus obviate acute BP rises (7,13). 
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Randomised controlled trials (RCTs) in patients with 
moderate to severe OSA 
Several RCTs looking at the effect of CPAP on ambulatory 
BP have been conducted in the past decades; the results of 
these trials have established that CPAP treatment of patients 
with moderate to severe symptomatic OSA lowers BP to a 
variable extent. Most of the trials reported a reduction in 
BP of between 2 and 10 mmHg after several weeks of CPAP 
therapy (13,14). The effect of CPAP therapy on BP seems 
to depend on the severity of the sleep disordered breathing, 
the presence of daytime sleepiness, the extent of obesity, BP 
values before CPAP treatment and hours of nightly CPAP 
use (15-17). The findings of recent studies suggest that, in 
symptomatic patients, the beneficial effects of CPAP on 
BP are found mainly in those who show good adherence to 
treatment (e.g., at least 4 h per night), and this may also be 
true for patients without overt daytime sleepiness (18,19).
RCTs in patients with mild OSA
A common question faced by sleep physicians is at which level 
of disease severity patients with OSA should be treated. There 
is particular uncertainty about the need and the effectiveness 
of treatment in mild cases of OSA, especially when 
treatment would be prescribed to reduce cardiovascular risk. 
Barnes et al. (20) performed a RCT in 28 patients with 
mild OSA [mean apnoea hypopnoea index (AHI) of 12.9/h], 
who underwent eight weeks of CPAP treatment vs. an 
oral placebo tablet. Compared to placebo, CPAP did not 
improve Epworth Sleepiness Scale (ESS) as a measure 
of daytime sleepiness. No benefit of CPAP compared to 
placebo was found on 24 h BP.
Newer data from a RCT conducted by Weaver et al. (21) 
evaluate the efficacy of CPAP treatment to improve 
functional status assessed by the Functional Outcomes of 
Sleep Questionnaire (FOSQ) in sleepy patients with mild 
and moderate OSA. A total of 239 patients with a mean 
AHI of about 13/h were randomized to CPAP treatment 
or placebo. After eight weeks CPAP treatment significantly 
improved the functional outcome of patients with mild OSA 
and there was a significant change in daytime diastolic BP 
values from baseline by −1.93 mmHg (95% CI, −3.8 to 0.0; 
P=0.048) between the two groups (21).
Both RCTs were not powered adequately to investigate 
the treatment effect on BP. Thus, further trials are needed 
to definitely clarify if patients with mild OSA benefit from 
CPAP treatment in terms of BP reduction.
RCTs in patients with oligo-symptomatic OSA 
Half of all individuals with moderate to severe OSA do not 
report excessive sleepiness (22,23). An association between 
oligo-symptomatic OSA and cardiovascular disease has not 
been established so far, and it is unclear whether CPAP 
treatment results in improved vascular risk in this group of 
patients.
Recently, Barbé and colleagues (24) published the data 
of a RCT which evaluated the effect of CPAP treatment 
on the incidence of hypertension and cardiovascular events 
in a cohort of non-sleepy patients with OSA. The 725 
consecutive patients with an AHI of ≥20/h and an ESS 
score of ≤10 were enrolled. In this cohort of OSA patients 
without daytime sleepiness, CPAP treatment did not result 
in a statistically significant reduction in the incidence of 
hypertension and cardiovascular events compared to usual 
care after a median follow-up of 4 years. However, there 
was some evidence that patients who were highly compliant 
with CPAP (>5.6 h/night) benefited from this treatment as 
a reduction of BP and cardiovascular events was observed in 
such patients (24).
In the Multicentre Obstructive Sleep Apnoea Interventional 
Cardiovascular (MOSAIC) trial 391 patients with oligo-
symptomatic OSA were randomised to 6 months of auto-
adjusting CPAP therapy or standard care. The investigators 
demonstrated that CPAP treatment significantly improved 
subjective daytime sleepiness (adjusted treatment effect on 
ESS −2.0; 95% CI, −2.6 to −1.4; P<0.0001). However, this 
positive treatment effect on symptoms was not accompanied 
by a reduction in calculated vascular risk or BP (25). 
The findings of the MOSAIC study were confirmed by a 
meta-analysis published by Bratton et al. (26), in which the 
individual data of 1,206 patients from four RCTs have been 
evaluated. Although CPAP treatment reduced OSA severity 
and sleepiness in minimally symptomatic patients, overall 
it did not to have a beneficial effect on BP, except in those 
patients who used CPAP for >4 h/night (26).
RCTs in patients with resistant hypertension
OSA has been proposed as a risk factor for resistant hypertension, 
which is defined as repeatedly measured BP >140/90 mmHg 
despite the use of three or more antihypertensive drugs of 
different classes. It has been estimated that more than 70% 
of patients with resistant hypertension have OSA (27).
There are a number of recently published RCTs on the 
effect of CPAP on BP in patients with resistant hypertension 
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(28-30). In a first RCT conducted by Lozano et al. (29), 
64 patients were randomised to receive CPAP added to 
conventional treatment or conventional medical treatment 
alone. They completed a follow-up after 3 months and 
patients who used CPAP >5.8 h showed a greater reduction 
than patients treated with standard medication in daytime 
diastolic BP −6.12 mmHg (95% CI, −1.45 to −10.82; 
P=0.004), 24-h diastolic BP 6.98 mmHg (95% CI, −1.86 
to −12.1; P=0.009) and 24-h systolic BP −9.71 mmHg (95% 
CI, −0.20 to −19.22; P=0.046). Additionally, the number of 
patients with a dipping pattern significantly increased in the 
CPAP group compared to conventional medical treatment 
(51.7% vs. 24.1%, P=0.008) (29).
Pedrosa et al. (28) randomised 20 patients with resistant 
hypertension to standard antihypertensive treatment and 
20 patients to antihypertensive treatment plus CPAP for 
6 months. Daytime ambulatory BP decreased significantly 
in the group allocated to antihypertensive treatment plus 
CPAP compared to standard antihypertensive treatment 
alone; the difference between groups in systolic and diastolic 
BP was also significant (9.6±6.6 and 6.6±4.6 mmHg; 
P<0.05). Interestingly, in this trial there was no beneficial 
effect of CPAP on nocturnal BP. This may be explained 
partly by recurrent arousals induced by the repetitive BP 
measurements during the night masking any underlying 
benefit, or the possibility that resistant hypertension is 
a hyperadrenergic condition that itself leads to frequent 
arousals (28). 
In the HIPARCO-trial (30), a Spanish multicentre 
RCT, 194 patients with resistant hypertension and an AHI 
of ≥15/h were randomised to CPAP in addition to standard 
antihypertensive treatment or antihypertensive medication 
alone. After 12 weeks of CPAP treatment a higher 
prevalence of nocturnal dipper pattern and a reduction of 
nocturnal riser pattern have been observed. The recovery 
of the nocturnal dipper pattern may be advantageous for 
long-term cardiovascular outcome as the presence of a non-
dipping or rising BP pattern is recognised as an independent 
cardiovascular risk factor (31). Linear regression analysis 
showed a reduction of 1.9 mmHg (95% CI, 0.6 to 3.3) in 
systolic BP and 1.0 mmHg (95 % CI, 0.1 to 1.8) in diastolic 
BP for each additional hour of CPAP use (30).
Meta-analyses
The extent to which CPAP can reduce BP in OSA patients 
is still under debate. Up to date, numerous meta-analyses 
evaluated the effects of CPAP on BP. In the following 
we focus on three recently published meta-analyses 
summarizing the relevant RCT data on the effect of CPAP 
therapy on BP (32-34).
Schein et al. (32) reviewed 16 RCTs which included 
1,166 OSA patients in total. The use of CPAP resulted in 
clinically relevant reductions of BP; CPAP treatment was 
associated with a reduction of systolic BP by 3.20 mmHg 
(95% CI, 1.72 to 4.67) and diastolic BP by 2.87 mmHg (95% 
CI, 0.55 to 5.18) (32).
A further meta-analysis by Montesi et al. (34) including 
32 RCTs showed similar results. OSA patients treated with 
CPAP benefitted from significant reductions in systolic BP 
by 2.58 mmHg (95% CI, 3.57 to 1.59) and diastolic BP by 
2.01 mmHg (95% CI, 2.84 to 1.18). Night-time systolic BP 
was the variable with the most prominent reduction after 
treatment with CPAP (4.09 mmHg, 95% CI, 6.24 to 1.94) (34).
In their recently published meta-analysis of 29 RCTs 
including 1,820 participants, Fava et al. (33) also observed 
a decreased systolic BP (2.6±0.6 mmHg) and diastolic BP 
(2.0±0.4 mmHg) in patients with CPAP treatment. As a 
result of their meta-regression analysis they concluded that 
patients with frequent apnoeic episodes may experience 
the largest benefit from CPAP therapy with regard to BP 
reductions; for each increase in AHI of 10/h the systolic 
BP was predicted to decrease approximately 1 mmHg with 
CPAP treatment (33). 
The relatively small treatment effects of CPAP on BP 
found in the meta-analyses may be related to methodological 
differences among the included trials, different study 
populations (e.g., sleepy and non-sleepy patients), sample 
sizes, study designs and the techniques used to measure BP 
(e.g., single time point, 24 h BP, beat-to-beat BP).
Clinical implications
Considering the recent RCT data, treatment with CPAP 
promotes small but clinically significant reductions in BP 
in individuals with OSA. Thus, a combined treatment 
including both antihypertensive medication and CPAP may 
be required in more severely hypertensive OSA patients. 
This combination is likely to be more effective in lowering 
both nocturnal and daytime BP than either treatment alone. 
The subsequent reduction in cardiovascular risk may be 
substantial, however this needs to be shown in a RCT (35,36). 
CPAP effects on endothelial and vascular function
Endothelial dysfunction is an early marker of vascular 
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damage that precedes clinically overt vascular disease and 
is an important predictor of cardiovascular events. Early 
recognition of atherosclerotic changes and endothelial 
dysfunction may have an impact on risk stratification and 
thus influence the clinician’s decision whether or not to 
aim for risk factor reduction in such patients. Evidence 
underpinning the association between OSA and impaired 
endothelial function and reduced endothelial repair capacity 
has been accumulating in recent years (37-41). 
One wel l-descr ibed mechanism of  endothel ia l 
dysfunction is the reduced bioavailability of endothelium-
derived vasodilating factors such as nitric oxide (NO). Flow-
mediated dilatation (FMD) of the brachial artery is currently 
the best-validated technique to non-invasively measure 
peripheral endothelial function. This method quantifies 
NO-mediated vasodilatation resulting from shear-stress 
mediated activation of endothelial NO synthase in response 
to an acute increase in luminal blood flow (42,43). 
A possible underlying mechanism for endothelial 
dysfunction in patients with OSA seems to be a down 
regulation of endothelial NO synthase as a result of increased 
sympathetic activity, oxidative stress, excessive arterial 
wall shear stress caused by recurrent surges in BP during 
apnoeic events, increased endothelial cell apoptosis as well as 
increased levels of coagulation factors and cholesterol (37,44). 
RCTs in patients with moderate to severe OSA 
The first RCT investigating the impact of CPAP therapy 
on FMD in moderate to severe OSA by Ip and colleagues (45) 
resulted in a significant increase of FMD in the CPAP group 
after four weeks of therapy, whereas those on standard care 
showed no significant change (absolute between-group 
difference in FMD of 5.4%, P<0.001).
In a RCT conducted by Kohler et al. (18) a significant decrease 
in endothelial function (FMD) was observed after 1 week [−1.7% 
(95% CI, −2.8 to −0.6); P<0.002] and 2 weeks [−3.2% (95% 
CI, −4.5 to −1.9); P<0.001] of CPAP withdrawal in patients 
with moderate-severe OSA compared to continued CPAP use. 
RCTs in patients with mild OSA
To date, there are no published data from RCTs on the effect 
of CPAP on endothelial function in patients with mild OSA.
RCTs in patients with oligo-symptomatic OSA 
Recent data from the MOSAIC-trial, a multicentre RCT 
evaluating the cardiovascular risk in 391 patients with 
minimally symptomatic OSA, CPAP treatment showed 
beneficial effects on endothelial function as assessed 
by FMD +2.1% (95% CI, 1.0 to 3.2; P<0.001). The 
improvement in FMD was larger in patients using CPAP 
for >4 h/night than in those who used it less (P<0.013) (46).
Meta-analysis
Between 2004 and 2013, 6 RCTs have been performed 
measuring FMD in patients with OSA before and after 
2-24 weeks of CPAP treatment. RCTs evidenced that CPAP 
treatment improves endothelial function. Compared to the 
control group, CPAP therapy significantly increased FMD 
by 3.9% (95% CI, 1.9 to 5.8, P<0.0001) (47).
CPAP effects on arterial stiffness
Increased arterial stiffness is an early indicator of arterial 
disease. Augmentation index (Aix) and pulse wave velocity 
(PWV) are measures of arterial stiffness and independently 
predict cardiovascular events in high-risk populations (48). 
The shape of the pressure waveform of an artery provides 
a measure of arterial stiffness and can be assessed by the 
technique of pulse wave analysis (49). 
RCTs in patients with moderate to severe OSA 
Drager et al. (50) randomly assigned 24 patients with severe 
OSA without comorbidities to receive no treatment or 
CPAP for 4 months. After this period of CPAP treatment 
they found a significant decrease of arterial stiffness as 
assessed by PWV (10.4±1.0 vs. 9.3±0.9 m/s; P<0.001) (50).
In another RCT by Kohler et al. (14) a significantly 
decreased Aix from 14.5% to 9.1% was observed in patients 
with moderate to severe OSA after 4 weeks of CPAP 
treatment compared to sham CPAP. This considerable 
reduction is comparable in size to the effect seen after 12 weeks 
of exercise training in patients with coronary artery disease 
or after 6 weeks of eprosartan (600 mg daily) in patients 
with never treated arterial hypertension (14).
In contrast, Jones et al. (51) could not find a significant 
decrease of Aix (15.5%±11.9% vs. 16.6%±11.7%; P=0.08) 
in 43 patients with an AHI >15/h after 12 weeks of CPAP 
or sham-CPAP treatment in their RCT. An important 
limitation of this study and possibly the reason why there 
was no significant effect of CPAP on Aix in the latter study 
is the very low nightly CPAP usage of 3 h/night (51).
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RCTs in patients with mild OSA
At present there are no data from RCTs evaluating the 
effects of CPAP therapy on arterial stiffness in patients with 
mild OSA.
RCTs in patients with oligo-symptomatic OSA
A recently published RCT assessed Aix by pulse wave 
analysis in 208 non-sleepy OSA patients who underwent 
6 months of CPAP treatment or continued standard care. 
There was no statistically significant effect of CPAP on 
Aix observed (−1.4%; 95% CI −3.6 to 0.9; P<0.23). An 
explanation for the lack of an effect in this study may be 
that the population of patients were not only non-sleepy 
but also had milder OSA than in the other published RCTs 
(50,52). In addition, the study population had a higher 
age and higher proportion of patients with cardiovascular 
comorbidities than those of previous studies, both of which 
are well known to increase arterial stiffness and, thus, may 
have masked a positive effect of CPAP (46).
Meta-analysis
A recently published meta-analysis by Vlachantoni et al. (48) 
included 615 patients from 11 interventional studies and 
four RCTs. Overall significant improvements were observed 
in all indices of arterial stiffness after CPAP treatment. 
Nevertheless, the potential beneficial effects of CPAP in 
reducing arterial stiffness in patients with mild OSA and the 
impact of CPAP adherence on the treatment effect should 
be explored in future studies (48).
CPAP effects on vascular events
Data from observational cohort studies suggest that OSA is 
associated with vascular morbidity and mortality (1,12). In 
contrast to these findings, Barbe and colleagues (24) as well 
as the investigators of the MOSAIC-trial (25), who analysed 
the effects of long-term CPAP therapy on cardiovascular risk 
in non-sleepy OSA patients could not establish a beneficial 
effect of CPAP treatment on cardiovascular events.
Thus evidence is needed from large RCTs to evaluate 
whether CPAP treatment is a useful therapy to prevent 
vascular events in patients with OSA. There is ongoing 
research in this field and data answering some of the open 
questions may soon be available (53). 
Promising is the Sleep Apnea Cardiovascular Endpoints 
Study SAVE (NCT00733343), a multi-centre, open label, 
parallel, prospective, RCT that investigates the effects 
of CPAP treatment plus standard care versus standard 
care alone in 2,500 high risk subjects for CAD with 
moderate-severe OSA. The trial will determine the effects 
of CPAP treatment over a 2-7-year follow-up period 
on new cardiovascular events, including MI, stroke and 
cardiovascular death. The study is conducted in China, 
Australia, New Zealand, Spain and Brazil and a completion 
of this trial is announced for December 2015 (5,54). 
Another large-scale multi-centre RCT (the Randomized 
Intervention with CPAP in Coronary Artery Disease 
and Sleep Apnoea-RICCADSA trial, NCT0051959) 
investigates patients with asymptomatic OSA and stable 
CAD. This study completed recruitment and included 511 
patients with CAD undergoing planned percutaneous or 
surgical coronary revascularization and assesses whether 
CPAP treatment reduces the combined rate of new 
revascularization, MI, stroke and cardiovascular mortality 
over a follow-up period of 3 years (55). 
ISAACC, another notable trial (CPAP in Patients 
With Acute Coronary Syndrome and OSA-trial, NCT 
01335087) will include more than 1,800 OSA patients with 
a recent acute coronary syndrome (ACS) to clarify whether 
CPAP treatment reduces the rate of major cardiovascular 
events in patients with non-ST elevation or ST elevation 
ACS admitted to a coronary care unit during a 12-month 
follow-up (53,56). 
The US National Institute of Health has funded three 
planning grants, the Heart Biomarker Evaluation in Apnea 
Treatment (HeartBEAT, NCT01086800), Best Apnea 
Interventions in Research (BestAIR, NCT01261390) and the 
Sleep Apnea in TIA/Stroke (SleepTight, NCT01446913) 
studies to evaluate design approaches for a large scale clinical 
trial of CPAP for cardiovascular risk reduction, including 
effectiveness of various recruitment strategies, methods 
for optimizing adherence, use of control treatments, 
intermediate endpoints most responsive to intervention and 
the use of oxygen as an alternative to CPAP (5).
Conclusions
Although numerous RCTs found clinically significant 
reductions of BP with CPAP treatment in patients with 
moderate to severe symptomatic OSA, CPAP indication 
is still debatable in patients with mild OSA or in patients 
without daytime sleepiness. Hence, OSA treatment must 
be tailored for each patient, based on metabolic and 
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cardiovascular risks and the willingness of patients to use 
CPAP on a nightly basis. Alternative or combined treatments 
are needed to reduce cardiovascular risk, particularly in 
minimally symptomatic patients, who are less likely to accept 
CPAP (57). The ongoing RCTs have to be awaited before 
CPAP therapy can be regarded as an effective treatment to 
protect from vascular morbidity and mortality (37).
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